Alberto Zambon Articles
![Statins and PCSK9 inhibitors in combination: Initial therapy in very high-risk patients in secondary prevention](https://www.pcsk9forum.org/wp-content/uploads/articleplaceholder-150x150.jpg)
Statins and PCSK9 inhibitors in combination: Initial therapy in very high-risk patients in secondary prevention
Reports from the 18th Virtual Closed Scientific Expert Meeting of the Editorial Board Alberto Zambon
read more »Posted on 5 July 2023 |
Posted by Alberto Zambon | Posted in Hot topics,
18th Closed Scientific Expert Meeting of the Editorial Board
![Play](https://www.pcsk9forum.org/wp-content/themes/pcsk9forumnew/images/play.png)
![ODYSSEY trials at ESC Congress Hotline](https://img.youtube.com/vi/ukjVq9lbIEY/0.jpg)
ODYSSEY trials at ESC Congress Hotline
ESC Congress 2014: Lipids Hotline: ODYSSEY TRIALS Prof Alberto Zambon, University of Padua, Italy discusses the four ODYSSEY trials with the PCSK9 inhibitor alirocumab presented at ESC Congress Hotline Sunday. Addition of a new investigational agent – Alirocumab – to high doses of statins result…
read more »Posted on 1 September 2014 |
Posted by Alberto Zambon | Posted in News,
Article Archive,
Videos,
European Society of Cardiology Congress 2014